Form Bio to showcase integrated AI and wet lab Gene Therapy Development solutions at Cell & Gene Meeting on the Mesa. Sep 28, 2026, 09:00 ET Form Bio's integrated AAV gene therapy platform connects AI-powered vector design, wet lab validation, and manufacturing and quality insights to help developers address challenges earlier in development. SAN CARLOS, Calif., Sept. 28, 2026 /PRNewswire-PRWeb/ - Form Bio, a leader in AI-powered solutions for genetic medicine and genome engineering, today announced that its leadership team will attend Cell & Gene Meeting on the Mesa 2026, where the company will showcase its integrated approach to gene therapy development that connects computational design, wet lab validation, and manufacturing and genomic quality control. As gene therapy programs advance, critical manufacturing challenges emerge only after a candidate has already been designed and selected, when making changes can be difficult and costly. Form Bio is bringing manufacturability considerations earlier into development, enabling researchers to assess sequence and vector characteristics that may influence manufacturing performance while designs can still be refined and optimized. "The industry has historically treated design and manufacturing as sequential but separate parts of development," said Michelle Chen, PhD, CEO of Form Bio. "We believe there is an opportunity to connect them much earlier. If you can identify manufacturing challenges while designing the AAV payload and vector sequence, you can make better-informed design decisions before they become costly downstream problems. Form Bio helps our partners address these challenges," said Dr. Chen. Bringing Manufacturability Into the Design Conversation Form Bio has expanded its platform over the past year to connect computational design with experimental validation and manufacturing-focused insights. The company recently opened its wet lab facility at MBC BioLabs in San Carlos, California, enabling researchers to connect computational predictions with biological evidence. This "Lab in the Loop" approach creates a continuous feedback cycle in which vector designs can be evaluated experimentally, with resulting data informing subsequent design iterations. By connecting design, validation, and manufacturing insights, developers can evaluate important characteristics earlier, when design decisions remain more flexible. Form Bio's integrated platform includes: * FormSightAI(TM): AI-powered computational platform for genetic medicine and vector design, enabling developers to design and optimize therapeutic constructs in silico. * FormLab: Integrated wet lab validation services that connect computational design with experimental data to validate and optimize genetic medicine candidates. * FormBatchQC(TM): Genomic quality and comparability analytics that assess genome integrity, detect impurities, and evaluate lot-to-lot consistency. * FormManufacturing(TM): End-to-end platform for designing, optimizing, and monitoring manufacturability from initial construct design through scale-up. Together, these capabilities support a more connected approach to development in which biological performance, quality, and manufacturability can be considered earlier, when design decisions remain more flexible. Customer programs have demonstrated up to 8x improvement in genome integrity, 2-3x higher manufacturing yield, and 5x improvement in controllable expression. Presenting & Attending at Cell & Gene Meeting on the Mesa 2026 Form Bio continues to grow customer programs and strategic collaborations spanning genetic medicine, cell and gene therapy, and genome engineering. President & CEO Michelle Chen, PhD, AVP of Genetic Medicine Chris Tan, PhD, and AVP of Business Development David Kiger will be on-site throughout the conference to connect with industry partners, prospective customers, investors, and collaborators. As part of the Innovation Spotlight, Dr. Tan will present: "Designed to Be Made: Solving Gene Therapy Development Problems Before They Start" Tuesday, October 6, 2026 | 4:00 PM MST The presentation will explore how decisions made during therapeutic design can influence downstream development and manufacturing, and how developers can incorporate manufacturability, quality, and safety considerations earlier in the process, when designs can still be refined and optimized. Form Bio leadership will be available throughout the conference to meet with partners, prospective customers, investors, and collaborators. To schedule a meeting at Meeting on the Mesa, please contact [email protected]. About Form Bio Form Bio is a leader in developing AI-powered solutions for genetic medicine and genome engineering. Since spinning out from Colossal Biosciences in 2022, the company has become a trusted innovation partner to cell and gene therapy developers and beyond. By combining advanced computational technologies with integrated wet lab validation in one connected platform, Form Bio delivers deep insights into genome integrity, optimized payload design, and other critical factors-enabling safer, more efficacious, and more manufacturable therapeutics. By reducing risk, shortening timelines, and optimizing outcomes, Form Bio helps drug developers accelerate the path from discovery to the clinic. For more information, visit www.formbio.com or follow 2womenshealth on LinkedIn. Media Contact SOURCE Form Bio

Form Bio has launched FormManufacturing, an AI-driven platform designed to predict, optimize and monitor manufacturability for cell and gene therapies from initial design through commercial scale-up. The platform initially focuses on adeno-associated virus (AAV) therapies. The platform combines AI-driven design optimisation to identify manufacturing risks before laboratory work begins with genomic quality analytics that track product integrity through scale-up. Form Bio reports customer programmes have achieved eight times improvement in genome integrity, two to three times increase in manufacturing yield and five times improvement in controllable expression. The launch addresses a critical industry challenge, as 74% of FDA rejections stem from quality or manufacturing issues. Form Bio, which spun out from Colossal Biosciences in 2022, will showcase the platform at the ASGCT Annual Meeting in Boston from 11–15 May.